Long-Term Follow-Up of HLA-A2+ Patients with High-Risk, Hormone-Sensitive Prostate Cancer Vaccinated with the Prostate Specific Antigen Peptide Homologue (PSA146-154)

Twenty-eight HLA-A2+ patients with high-risk, locally advanced or metastatic, hormone-sensitive prostate cancer were immunized with a peptide homologue of prostate-specific antigen, PSA146-154, between July 2002 and September 2004 and monitored for clinical and immune responses. Fifty percent of the...

Descripción completa

Detalles Bibliográficos
Autores principales: Perambakam, Supriya, Xie, Hui, Edassery, Seby, Peace, David J.
Formato: Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2010
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3022181/
https://www.ncbi.nlm.nih.gov/pubmed/21253471
http://dx.doi.org/10.1155/2010/473453

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3022181/
https://www.ncbi.nlm.nih.gov/pubmed/21253471
http://dx.doi.org/10.1155/2010/473453

Ejemplares similares